US Listing is beneficial to AKE shareholders only if there is a premium attached to it. No longer the case and in fact being tied to Livent is a millstone around AKE's neck.
Under current pricing having a hydroxide plant in the US weighs down Livent's own non-conversion earnings. HYdroxide prices are similar to Carbonate and in China, and at times prices at a discount to Carbonate. What expertise do they bring to the table that AKE with a commissioned Naraha doesn't already have?
At current market prices, there is NO shortage of buyers for AKE's current or future production. AKE has a proven track record for some years now and we do not need Tesla to lend us any credibility ( not intended as a slight to Tesla ).
Signed off by a bunch of stupid shareholders
AKE Price at posting:
$8.72 Sentiment: Buy Disclosure: Held
